{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:49:47Z","timestamp":1788997787279,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the efficacy of <jats:italic>Lactobacillus paracasei<\/jats:italic> CNCM I-1572 (L. casei DG\u00ae) in both prevention of symptomatic recurrences and improvement of quality of life in patients with chronic bacterial prostatitis (CBP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with CBP attending a single Urological Institution were enrolled in this phase IV study. At enrollment, all patients were treated with antibiotics in agreement with EAU guidelines and then were treated with L. casei DG\u00ae (2 capsules\/day for 3\u00a0months). Clinical and microbiological analyses were carried out before (enrollment, T0) and 6\u00a0months (T2) after the treatment. Both safety and adherence to the treatment were evaluated 3\u00a0months (T1) after the enrollment. NIH Chronic Prostatitis Symptom Index (CPSI), International Prostate Symptom Score (IPSS) and Quality of Well-Being (QoL) questionnaires were used. The outcome measures were the rate of symptomatic recurrence, changes in questionnaire symptom scores and the reduction of antibiotic use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eighty-four patients were included. At T2, 61 patients (72.6%) reported a clinical improvement of symptoms with a return to their clinical status before symptoms. A time dependent improvement in clinical symptoms with significant changes in NIH-CPSI, IPSS and QoL (mean difference T2 vs T0: 16.5\u2009\u00b1\u20093.58; \u2212\u00a011.0\u2009\u00b1\u20094.32;\u2009+\u20090.3\u2009\u00b1\u20090.09; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), was reported. We recorded that L. casei DG\u00ae treatment induced a statistically significant decrease in both (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) symptomatic recurrence [1.9\/3\u00a0months vs 0.5\/3\u00a0months] and antibiotic use [\u2212\u00a07938 UDD]. No clinically relevant adverse effects were reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>L. casei DG\u00ae prevents symptomatic recurrences and improves the quality of life in patients with CBP, reducing the antibiotic use.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-020-03580-7","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T06:29:03Z","timestamp":1610605743000},"page":"3433-3440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The use of Lactobacillus casei DG\u00ae prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: results from a phase IV study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7234-3526","authenticated-orcid":false,"given":"Tommaso","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gallelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Cione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Perletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciarleglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Malossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"De Pretis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truls E. Bjerklund","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"issue":"6","key":"3580_CR1","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.juro.2007.08.046","volume":"178","author":"R Bartoletti","year":"2007","unstructured":"Bartoletti R, Cai T, Mondaini N et al (2007) Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis\/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multi center case-control observational study. J Urol 178(6):2411\u20132415","journal-title":"J Urol"},{"key":"3580_CR2","doi-asserted-by":"crossref","unstructured":"Bartoletti R, Cai T, Nesi G, Albanese S, Meacci F, Mazzoli S, Naber K. (2014) The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study.World J Urol 32(3):737\u2013742.","DOI":"10.1007\/s00345-013-1145-9"},{"issue":"4","key":"3580_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4081\/aiua.2018.4.227","volume":"90","author":"V Magri","year":"2019","unstructured":"Magri V, Boltri M, Cai T, Colombo R, Cuzzocrea S, De Visschere P, Giuberti R, Granatieri CM, Latino MA, Largan\u00e0 G, Leli C, Maierna G, Marchese V, Massa E, Matteelli A, Montanari E, Morgia G, Naber KG, Papadouli V, Perletti G, Rekleiti N, Russo GI, Sensini A, Stamatiou K, Trinchieri A, Wagenlehner FME (2019) Multidisciplinary approach to prostatitis. Arch Ital Urol Androl 90(4):227\u2013248","journal-title":"Arch Ital Urol Androl"},{"issue":"2","key":"3580_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.eururo.2006.07.016","volume":"51","author":"G Penna","year":"2007","unstructured":"Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, Fibbi B, Colli E, Maggi M, Adorini L (2007) Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis\/chronicpelvicpainsyndrome and benignprostatichyperplasia. Eur Urol 51(2):524\u2013533","journal-title":"Eur Urol"},{"issue":"2","key":"3580_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5534\/wjmh.2017.35.2.120","volume":"35","author":"T Cai","year":"2017","unstructured":"Cai T, Verze P, La Rocca R, Palmieri A, Tiscione D, Luciani LG, Mazzoli S, Mirone V, Malossini G (2017) The Clinical Efficacy of Pollen Extract and Vitamins on Chronic Prostatitis\/Chronic Pelvic Pain Syndrome Is Linked to a Decrease in the Pro-Inflammatory Cytokine Interleukin-8. World J Mens Health 35(2):120\u2013128","journal-title":"World J Mens Health"},{"key":"3580_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/gutjnl-2011-300971","volume":"61","author":"K Tsilingiri","year":"2012","unstructured":"Tsilingiri K, Barbosa T, Penna G et al (2012) Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. Gut 61:1007\u20131015","journal-title":"Gut"},{"issue":"1","key":"3580_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12876-017-0605-x","volume":"17","author":"D Compare","year":"2017","unstructured":"Compare D, Rocco A, Coccoli P, Angrisani D, Sgamato C, Iovine B, Salvatore U, Nardone G (2017) Lactobacillus Casei DG and Its Postbiotic Reduce the Inflammatory Mucosal Response: An Ex-Vivo Organ Culture Model of Post-Infectious Irritable Bowel Syndrome. BMC Gastroenterol 17(1):53","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"3580_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.4103\/1008-682X.131064","volume":"16","author":"E Vicari","year":"2014","unstructured":"Vicari E, La Vignera S, Castiglione R, Condorelli RA, Vicari LO, Calogero AE (2014) Chronic Bacterial Prostatitis and Irritable Bowel Syndrome: Effectiveness of Treatment With Rifaximin Followed by the Probiotic VSL#3. Asian J Androl 16(5):735\u2013739","journal-title":"Asian J Androl"},{"issue":"6","key":"3580_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ijantimicag.2008.11.012","volume":"33","author":"T Cai","year":"2009","unstructured":"Cai T, Mazzoli S, Bechi A et al (2009) Serenoarepens associated with Urticadioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int J Antimicrob Agents 33(6):549\u2013553","journal-title":"Int J Antimicrob Agents"},{"key":"3580_CR10","unstructured":"Trinchieri A. Role of levofloxacin in the treatment of urinary tract infections. Arch Ital UrolAndrol2001;73:105\u201313."},{"key":"3580_CR11","unstructured":"Bonkat G, Bartoletti R, Cai T et al. EAU guidelines on urological infections (2019). https:\/\/uroweb.org\/guideline\/urological-infections"},{"issue":"6","key":"3580_CR12","first-page":"1109","volume":"53","author":"DL Monnet","year":"2004","unstructured":"Monnet DL, M\u00f6lstad S, Cars O (2004) Defined daily doses of antimicrobials reflect antimicrobial prescriptions in ambulatory care. J AntimicrobChemother 53(6):1109\u20131111","journal-title":"J AntimicrobChemother"},{"issue":"6","key":"3580_CR13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.4111\/icu.2017.58.6.460","volume":"58","author":"T Cai","year":"2017","unstructured":"Cai T, Pisano F, Nesi G, Magri V, Verze P, Perletti G, Gontero P, Mirone V, Bartoletti R (2017) Chlamydia trachomatis versus common uropathogens as a cause of chronic bacterial prostatitis: is there any difference? results of a prospective parallel-cohort study. Investig Clin Urol 58(6):460\u2013467","journal-title":"Investig Clin Urol"},{"issue":"6","key":"3580_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1043-6618(03)00003-3","volume":"47","author":"L Gallelli","year":"2003","unstructured":"Gallelli L, Ferreri G, Colosimo M, Pirritano D, Flocco MA, Pelaia G, Maselli R, De Sarro GB (2003) Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro. Italy Pharmacol Res 47(6):493\u2013499","journal-title":"Italy Pharmacol Res"},{"key":"3580_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.eururo.2004.12.025","volume":"47","author":"G Giubilei","year":"2005","unstructured":"Giubilei G, Mondaini N, Crisci A, Raugei A, Lombardi G, Travaglini F et al (2005) The Italian version of the National Institutes of Health Chronic prostatitis symptom index. Eur Urol 47:805\u2013811","journal-title":"Eur Urol"},{"key":"3580_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000474438","volume":"31","author":"X Badia","year":"1997","unstructured":"Badia X, Garcia-Losa M, Dal-Re R (1997) Ten-language translation and harmonizationof the International Prostate Symptom Score: developing a methodology for multinational clinical trials. Eur Urol 31:129\u2013140","journal-title":"Eur Urol"},{"key":"3580_CR17","unstructured":"Kaplan RM, Bush JW, Berry CC: Health status: types of validity and the index of wellbeing. Health Serv Res 1976;11: 478\u2013507"},{"key":"3580_CR18","first-page":"843","volume":"165","author":"JC Nickel","year":"2001","unstructured":"Nickel JC, Downey J, Hunter D, Clark J (2001) Prevalence of prostatitis-like symptoms population based study using the National Institutes of Health chronic prostates symptoms index. J Urol 165:843\u2013845","journal-title":"J Urol"},{"key":"3580_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12820","volume":"505","author":"LA David","year":"2014","unstructured":"David LA, Maurice CF, Carmody RN et al (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505:559\u2013563. https:\/\/doi.org\/10.1038\/nature12820","journal-title":"Nature"},{"issue":"3","key":"3580_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41391-018-0041-1","volume":"21","author":"CM Porter","year":"2018","unstructured":"Porter CM, Shrestha E, Peiffer LB, Sfanos KS (2018) The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis 21(3):345\u2013354","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3580_CR21","doi-asserted-by":"crossref","unstructured":"Chiancone F, Carrino M, Meccariello C, Pucci L, Fedelini M, Fedelini P.The Use of a Combination of Vaccinium Macracarpon, Lyciumbarbarum L. and Probiotics (Bifiprost\u00ae) for the Prevention of Chronic Bacterial Prostatitis: A Double-Blind Randomized Study.Urol Int. 2019;103(4):423\u2013426.","DOI":"10.1159\/000502765"},{"key":"3580_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/00004836-200603000-00020","volume":"40","author":"M Camilleri","year":"2006","unstructured":"Camilleri M (2006) Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 40:264\u2013269","journal-title":"J Clin Gastroenterol"},{"issue":"11","key":"3580_CR23","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3945\/jn.114.197723","volume":"144","author":"C Ferrario","year":"2014","unstructured":"Ferrario C, Taverniti V, Milani C, Fiore W, Laureati M, De Noni I, Stuknyte M, Chouaia B, Riso P, Guglielmetti S (2014) Modulation of Fecal Clostridiales Bacteria and Butyrate by Probiotic Intervention with Lactobacillus paracasei DG Varies among Healthy Adults. J Nutr 144(11):1787\u20131796","journal-title":"J Nutr"},{"issue":"4","key":"3580_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/2050640617736478","volume":"6","author":"C Cremon","year":"2018","unstructured":"Cremon C, Guglielmetti S, Gargari G, Taverniti V, Castellazzi AM, Valsecchi C, Tagliacarne C, Fiore W, Bellini M, Bertani L, Gambaccini D, Cicala M, German\u00e0 B, Vecchi M, Pagano I, Barbaro MR, Bellacosa L, Stanghellini V, Barbara G (2018) Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterol J. 6(4):604\u2013613","journal-title":"United European Gastroenterol J."},{"key":"3580_CR25","doi-asserted-by":"crossref","unstructured":"Balzaretti S, Taverniti V, Guglielmetti S, Fiore W, Minuzzo M,Ngo HN, Ngere JB, Sadiq S, Humphreys PN, Laws AP. A novel rhamnose-rich hetero-exopolysaccharide isolated from Lactobacillus paracasei DG activates THP-1 human monocytic cells. Appl Environ Microbiol. 2017; 17;83(3). pii: e02702\u201316","DOI":"10.1128\/AEM.02702-16"},{"issue":"21","key":"3580_CR26","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.3748\/wjg.v21.i21.6698","volume":"21","author":"OA Paoluzi","year":"2015","unstructured":"Paoluzi OA, Del Vecchio BG, Visconti E, Coppola M, Fontana C, Favaro M, Pallone F (2015) Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World J Gastroenterol 21(21):6698\u20136705","journal-title":"World J Gastroenterol"},{"key":"3580_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1159\/000019784","volume":"34","author":"TE Bjerklund Johansen","year":"1998","unstructured":"Bjerklund Johansen TE, Gr\u00fcneberg RN, Guibert J, Hofstetter A, Lobel B, Naber KG et al (1998) The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol 34:457\u2013466","journal-title":"Eur Urol"},{"key":"3580_CR28","unstructured":"Thomas Jaeger and Ravi Deshpande. Choosing a Phase IV Study Design. Phase 4 Health Inc. Canadian Pharmaceutical Marketing\/Winter 2003 available at: http:\/\/www.stacommunications.com\/journals\/pdfs\/cpm\/cpmwinter03\/phasefour.pdf"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03580-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-020-03580-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03580-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T01:35:22Z","timestamp":1634088922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-020-03580-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["3580"],"URL":"https:\/\/doi.org\/10.1007\/s00345-020-03580-7","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"25 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Tommaso Cai and Alessandro Palmieri received travelling and speaking grants from SOFAR Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval protocol number 258, 2019.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Before the beginning of the study, the enrolled patients or legal guardians signed the informed consent. All data recorded in this study, i.e., anamnestic, clinical, and laboratory data, containing sensitive information were deidentified to ensure analysis of anonymous data only. This process was performed by non-medical staff using dedicated software.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}